EPS for Sarepta Therapeutics Inc (SRPT) Expected At $-0.88

October 13, 2017 - By Richard Conner

 EPS for Sarepta Therapeutics Inc (SRPT) Expected At $ 0.88
Investors sentiment increased to 1.52 in Q2 2017. Its up 0.09, from 1.43 in 2017Q1. It is positive, as 19 investors sold Sarepta Therapeutics Inc shares while 41 reduced holdings. 30 funds opened positions while 61 raised stakes. 41.29 million shares or 4.20% more from 39.62 million shares in 2017Q1 were reported.
National Bank Of America Corporation De holds 53,920 shares or 0% of its portfolio. Alliancebernstein Ltd Partnership owns 118,310 shares or 0% of their US portfolio. Raymond James Financial Advsr invested in 0% or 20,871 shares. Lehman Financial Resources Inc reported 0.13% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Sit Associate reported 0.02% stake. The Michigan-based Sigma Planning has invested 0.07% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Morgan Stanley invested 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Point72 Asia (Hong Kong) Ltd holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 78 shares. Utd Cap Finance Advisers Ltd Com, California-based fund reported 25,458 shares. First Allied Advisory Svcs stated it has 9,026 shares. Jabre Cap Ptnrs Sa reported 13,000 shares or 0.04% of all its holdings. 5,823 were reported by Natl Planning Corp. California Pub Employees Retirement Systems invested 0.01% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Rock Springs Capital Mgmt Ltd Partnership holds 0.35% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 205,000 shares. Eagle Asset Inc reported 0.16% in Sarepta Therapeutics Inc (NASDAQ:SRPT).

Investors wait Sarepta Therapeutics Inc (NASDAQ:SRPT) to report on October, 26. its quarterly earnings Wall Street analysts expect $-0.88 earnings per share, up $0.22 or 20.00 % from last year’s $-1.1 same quarter earnings. Sarepta Therapeutics Inc’s Wall Street analysts see -23.48 % EPS growth, taking into account the $-1.15 EPS reproted in the previous quarter, The stock increased 0.21% or $0.11 during the last trading session, reaching $51.28. About 1.51 million shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since October 13, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 26 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 19 have Buy rating, 1 Sell and 6 Hold. Therefore 73% are positive. Sarepta Therapeutics had 88 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, January 4. William Blair maintained the shares of SRPT in report on Wednesday, August 26 with “Buy” rating. As per Thursday, October 27, the company rating was initiated by Morgan Stanley. The stock has “Neutral” rating by Suntrust Robinson on Friday, August 7. The rating was maintained by Credit Suisse on Wednesday, June 28 with “Buy”. The stock has “Outperform” rating by Wedbush on Monday, October 10. The rating was maintained by Oppenheimer with “Buy” on Thursday, July 20. The rating was downgraded by JMP Securities to “Underperform” on Wednesday, March 23. The rating was downgraded by SunTrust to “Reduce” on Tuesday, April 26. Jefferies initiated it with “Hold” rating and $28 target in Friday, October 23 report.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Marketwatch.com which released: “Sarepta shares rise nearly 3% premarket after RBC sees ‘compelling’ argument …” on October 09, 2017, also Seekingalpha.com with their article: “Sarepta Therapeutics’ (SRPT) CEO Doug Ingram on Baird 2017 Global Healthcare …” published on September 14, 2017, Globenewswire.com published: “Sarepta Therapeutics Appoints Guriqbal S. Basi, Ph.D. as Chief Scientific Officer” on September 25, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “Sarepta: Uncertainties And Controversies Surround Its Trials” published on September 28, 2017 as well as Marketwatch.com‘s news article titled: “Sarepta Therapeutics shares surge 7.5% after Morgan Stanley upgrade” with publication date: October 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com